Roxadustat

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Renal Anemia

Conditions

Renal Anemia

Trial Timeline

Jun 1, 2020 → Jun 23, 2025

NCT ID

NCT04408820

About Roxadustat

Roxadustat is a pre-clinical stage product being developed by Astellas Pharma for Renal Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04408820. Target conditions include Renal Anemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05970172	Phase 3	Recruiting	Jan 16, 2024	Oct 30, 2027	Chronic Kidney Disease
NCT04408820	Pre-clinical	Completed	Jun 1, 2020	Jun 23, 2025	Renal Anemia
NCT04076943	Phase 2	Completed	Aug 20, 2019	Apr 23, 2021	Chemotherapy Induced Anemia
NCT03960489	Phase 1	Completed	Jul 31, 2019	Oct 14, 2019	Healthy Adult Subjects
NCT02964936	Phase 3	Completed	Jan 11, 2017	Aug 15, 2018	Chronic Kidney Disease
NCT02965040	Phase 1	Completed	Dec 12, 2016	Dec 11, 2017	Normal Renal Function
NCT02780726	Phase 3	Completed	Jun 22, 2016	Aug 2, 2017	Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
NCT02780141	Phase 3	Completed	Jun 2, 2016	Dec 12, 2017	ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02779764	Phase 3	Completed	May 16, 2016	Nov 28, 2017	Hemodialysis Patients With Renal Anemia
NCT01630889	Phase 2	Completed	May 18, 2012	Dec 12, 2019	Chronic Kidney Disease
NCT01244763	Phase 2	Completed	Oct 29, 2010	Jun 13, 2012	Chronic Kidney Disease
NCT01083888	Phase 1	Completed	Feb 15, 2010	Jun 7, 2010	Anemia

Competing Products

20 competing products in Renal Anemia

See all competitors

Product	Company	Stage	Hype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109	MBX Biosciences	Phase 1	28
LY3473329	Eli Lilly	Phase 1	33
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	44
SPR001	Spruce Biosciences	Phase 2	44
SPR001	Spruce Biosciences	Phase 2	44
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	44
Tildacerfont	Spruce Biosciences	Phase 2	44
Drotrecogin alfa activated (Xigris)	Eli Lilly	Phase 2	52
LY3819469	Eli Lilly	Phase 1	33
Atezolizumab + Cabozantinib	Chugai Pharmaceutical	Phase 3	77
DS-6000a + DS-6000a	Daiichi Sankyo	Phase 1	33
DS-1093a	Daiichi Sankyo	Phase 1	33
CS-3150	Daiichi Sankyo	Phase 3	77
AGS-16C3F	Astellas Pharma	Phase 1	33
AGS-16M8F	Astellas Pharma	Phase 1	33
CP-461	Astellas Pharma	Phase 2	52
roxadustat	Astellas Pharma	Phase 3	77
YM178	Astellas Pharma	Phase 1	33
intravenous immunoglobulins (IVIG)	Astellas Pharma	Phase 1	33
bixalomer	Astellas Pharma	Pre-clinical	23

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved